News
Archives
- 2020
- Oct (1)
- Jul (1)
- Apr (1)
- 2019
- Dec (1)
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2018
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
29 Apr 2013
First investigator meeting for our new North Asia sites for the first time
This April, our group conducted our first investigator meeting for our new North Asia sites for the first time. The North Asia meeting was hosted by Dr Thomas Yau and team at Queen Mary Hospital, Hong Kong. There was a commitment to develop the group as a formal trials network, to expand study collaborations over and above ASCOLT.